Orticumab

Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.[1]

Orticumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	oxLDL
Clinical data
ATC code	none
Identifiers
CAS Number	1314241-10-5
ChemSpider	none
UNII	2O892R8U24

References

World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Human	Burosumab Denosumab
Humanized	Blosozumab^† Romosozumab

Musculoskeletal

Human	Stamulumab^†

Human	Alirocumab Ascrinvacumab^§ Bentracimab^† Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab^‡ Imciromab^‡
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Demcizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Human	Aducanumab Erenumab Fasinumab^† Fulranumab Gantenerumab^† Opicinumab
Humanized	Bapineuzumab^† Crenezumab^† Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Solanezumab Tanezumab^†

Angiogenesis inhibitor

Humanized	Ranibizumab

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.